25 Jul, EOD - Indian

SENSEX 80039.8 (-0.14)

Nifty 50 24406.1 (-0.03)

Nifty Bank 50888.75 (-0.83)

Nifty IT 40055.45 (-0.15)

Nifty Midcap 100 56741.75 (-0.23)

Nifty Next 50 72210.25 (0.51)

Nifty Pharma 21105.5 (0.94)

Nifty Smallcap 100 18673.05 (-0.27)

25 Jul, EOD - Global

NIKKEI 225 37869.51 (-3.28)

HANG SENG 17004.97 (-1.77)

DOW JONES 39853.87 (-1.25)

S&P 5427.13 (-2.31)

Login/Signup

Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(13 Jun 2024, 12:18)

Dr Reddy’s arm inks pact with Ingenus Pharma to market Cyclophosphamide Injection

Dr Reddy’s Laboratories said that its wholly owned subsidiary, Dr. Reddy’s USA and Ingenus Pharmaceuticals has entered into license agreement to commercialise Cyclophosphamide Injection RTD in United States (US).

Dr Reddy’s USA has licensed from Ingenus the exclusive rights to commercialise Cyclophosphamide injection in strengths of 500 mg/2.5mL; 1g/5mL; and 2g/10mL in US.

Cyclophosphamide is used to treat cancer of the ovaries, breast, blood and lymph system, and nerves (mainly in children). Cyclophosphamide is also used for retinoblastoma (a type of eye cancer mainly in children), multiple myeloma (cancer in the bone marrow), and mycosis fungoides (tumors on the skin).

Dr. Reddy’s USA will commercialise the Cyclophosphamide injection in the United States and will pay Ingenus 50% of the estimated profit share, with no further consideration payable.

The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr. Reddy’s USA.

Accor...

More News
More Company News View Company Information